Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.43 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.43 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.41 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780110 | 0.98 | DRD2 (0.58) | DRD2DRD3TAAR1ADRA2AADRA2B | |
| SCHEMBL9281325 | 0.87 | TAAR1 (0.52) | DRD2DRD3TAAR1ADRA2AADRA2B | |
| SCHEMBL5270807 | 0.82 | TAAR1 (0.48) | DRD2DRD3TAAR1ALDH1A1MAPK1 | |
| SCHEMBL10937071 | 0.81 | DRD2 (0.49) | DRD2DRD3TAAR1ADRA2AADRA2B | |
| SCHEMBL9309832 | 0.81 | DRD2 (0.47) | DRD2DRD3TAAR1ALDH1A1TRPM8 | |
| Hydrochloric Acid SCHEMBL4599895 | 0.80 | KDM4E (0.53) | DRD2DRD3TAAR1ADRA2AADRA2B | |
| SCHEMBL2376616 | 0.78 | TAAR1 (0.54) | DRD2DRD3TAAR1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11105872 | 0.77 | — | — | |
| SCHEMBL21034335 | 0.76 | DRD2 (0.55) | DRD2DRD3TAAR1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL9740413 | 0.76 | DRD2 (0.48) | DRD2DRD3TAAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014128523-A1 | A PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES | Piramal Enterprises Limited (IN) | 2014-08-28 | — | — | WO | claimed |
| WO-2014128524-A1 | AN IMPROVED PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES | Piramal Enterprises Limited (IN) | 2014-08-28 | — | — | WO | claimed |
| EP-0136649-A2 | Process for the preparation of cationic vinyl ester based polymer latices and their use as formaldehyde-free binders. | National Starch and Chemical Corporation (US) | 1985-04-10 | — | — | EP | claimed |
| US-4489192-A | QUATERNARY AMMONIUM MONOMER | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1984-12-18 | — | — | US | claimed |
| US-20250115545-A1 | TERPENE-CONTAINING LIPIDOIDS FOR GENE DELIVERY | UNIV OF SAN DIEGO (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250099383-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | UNIVERSITY OF SAN DIEGO | 2025-03-27 | — | — | US | disclosed |
| EP-4231999-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | POSEIDA THERAPEUTICS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4465962-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | Poseida Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-4466249-A2 | TERPENE-CONTAINING LIPIDOIDS FOR GENE DELIVERY | University of San Diego (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240018101-A1 | MULTIVALENT TERPENE-BASED BOLAAMPHIPHILES FOR GENE DELIVERY | UNIVERSITY OF SAN DIEGO | 2024-01-18 | — | — | US | disclosed |
| US-20240000969-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | UNIVERSITY OF SAN DIEGO | 2024-01-04 | — | — | US | disclosed |
| EP-4232015-A1 | MULTIVALENT TERPENE-BASED BOLAAMPHIPHILES FOR GENE DELIVERY | University of San Diego (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-0170095-B1 | ONE-PACKAGE AQUEOUS LATICES CONTAINING ALKALINE-CURABLE CROSSLINKING POLYMERS | National Starch and Chemical Corporation (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0136649-B1 | PROCESS FOR THE PREPARATION OF CATIONIC VINYL ESTER BASED POLYMER LATICES AND THEIR USE AS FORMALDEHYDE-FREE BINDERS. | National Starch and Chemical Corporation (US) | 1989-11-15 | — | — | EP | disclosed |
| US-4837227-A | ANALGESICS, ANTIDEPRESSANTS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0270692-A1 | ANTIARRHYTHMIC AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-06-15 | — | — | EP | disclosed |
| US-4546140-A | STORAGE STABILITY | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1985-10-08 | — | — | US | disclosed |
| EP-0136649-A2 | Process for the preparation of cationic vinyl ester based polymer latices and their use as formaldehyde-free binders. | National Starch and Chemical Corporation (US) | 1985-04-10 | — | — | EP | disclosed |
| US-4489192-A | QUATERNARY AMMONIUM MONOMER | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1984-12-18 | — | — | US | disclosed |
| US-4460405-A | Dichloroacetyl thioesters as herbicidal antidotes | STAUFFER CHEMICAL CO. (US) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115545-A1 | TERPENE-CONTAINING LIPIDOIDS FOR GENE DELIVERY | TTPA, NR1H2, NR1H3 | DRD2 4345/4885DRD3 3844/4885ADRA2A 2070/4885 |
| US-20240000969-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | LIPC, CD4, HAVCR2 | DRD2 4847/4885DRD3 4759/4885ADRA2A 4487/4885 |
| US-20240018101-A1 | MULTIVALENT TERPENE-BASED BOLAAMPHIPHILES FOR GENE DELIVERY | BOLA2; BOLA2B, GHITM, GGPS1 | DRD2 3628/4885DRD3 3783/4885ADRA2A 874/4885 |
| US-20250099383-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | POLRMT, RNMT, SNRPE | DRD2 4665/4885DRD3 4428/4885ADRA2A 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.